These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 34088965)
21. Is pulmonary artery a dose-limiting organ at risk in non-small cell lung cancer patients treated with definitive radiotherapy? Ma JT; Sun L; Sun X; Xiong ZC; Liu Y; Zhang SL; Huang LT; Han CB Radiat Oncol; 2017 Feb; 12(1):34. PubMed ID: 28143532 [TBL] [Abstract][Full Text] [Related]
22. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base. Sher DJ; Koshy M; Liptay MJ; Fidler MJ Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108 [TBL] [Abstract][Full Text] [Related]
23. Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival. Kiss N; Beraldo J; Everitt S Support Care Cancer; 2019 Jul; 27(7):2657-2664. PubMed ID: 30478673 [TBL] [Abstract][Full Text] [Related]
24. Impact of Skeletal Muscle Mass Index, Intramuscular Adipose Tissue Content, and Visceral to Subcutaneous Adipose Tissue Area Ratio on Early Mortality of Living Donor Liver Transplantation. Hamaguchi Y; Kaido T; Okumura S; Kobayashi A; Shirai H; Yagi S; Kamo N; Okajima H; Uemoto S Transplantation; 2017 Mar; 101(3):565-574. PubMed ID: 27926595 [TBL] [Abstract][Full Text] [Related]
25. Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer. Minami S; Ihara S; Tanaka T; Komuta K World J Oncol; 2020 Feb; 11(1):9-22. PubMed ID: 32095185 [TBL] [Abstract][Full Text] [Related]
26. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer. Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101 [TBL] [Abstract][Full Text] [Related]
27. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy. Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887 [TBL] [Abstract][Full Text] [Related]
28. Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy. Rom H; Tamir S; Van Vugt JLA; Berger Y; Perl G; Morgenstern S; Tovar A; Brenner B; Benchimol D; Kashtan H; Sadot E Ann Surg Oncol; 2022 Mar; 29(3):1553-1563. PubMed ID: 34716836 [TBL] [Abstract][Full Text] [Related]
29. Relationship Between Preoperative Sarcopenia Status and Immuno-nutritional Parameters in Patients with Early-stage Non-small Cell Lung Cancer. Shoji F; Matsubara T; Kozuma Y; Haratake N; Akamine T; Takamori S; Katsura M; Toyokawa G; Okamoto T; Maehara Y Anticancer Res; 2017 Dec; 37(12):6997-7003. PubMed ID: 29187486 [TBL] [Abstract][Full Text] [Related]
30. Optimizing Survival of Patients With Marginally Operable Stage IIIA Non-Small-Cell Lung Cancer Receiving Chemoradiotherapy With or Without Surgery. Yang KL; Chang YC; Ko HL; Chi MS; Wang HE; Hsu PS; Lin CC; Yeh DY; Kao SJ; Jiang JS; Chi KH Clin Lung Cancer; 2016 Nov; 17(6):550-557. PubMed ID: 27378175 [TBL] [Abstract][Full Text] [Related]
31. DART-bid (Dose-differentiated accelerated radiation therapy, 1.8 Gy twice daily)--a novel approach for non-resected NSCLC: final results of a prospective study, correlating radiation dose to tumor volume. Wurstbauer K; Deutschmann H; Dagn K; Kopp P; Zehentmayr F; Lamprecht B; Porsch P; Wegleitner B; Studnicka M; Sedlmayer F Radiat Oncol; 2013 Mar; 8():49. PubMed ID: 23497555 [TBL] [Abstract][Full Text] [Related]
32. Impact of sarcopenia on survival of pancreatic cancer patients treated with concurrent chemoradiotherapy. Cho WK; Yu JI; Park HC; Lim DH; Kim TH; Chie EK Tumori; 2021 Jun; 107(3):247-253. PubMed ID: 32646298 [TBL] [Abstract][Full Text] [Related]
33. Concurrent Daily Cisplatin and High-Dose Radiation Therapy in Patients With Stage III Non-Small Cell Lung Cancer. Dieleman EMT; Uitterhoeve ALJ; van Hoek MW; van Os RM; Wiersma J; Koolen MGJ; Kolff MW; Koning CCE; Adam JA; Verberne HJ; Annema JT; Rasch CRN Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):543-551. PubMed ID: 30055239 [TBL] [Abstract][Full Text] [Related]
34. Severe muscle loss during radical chemoradiotherapy for non-metastatic nasopharyngeal carcinoma predicts poor survival. Huang X; Ma J; Li L; Zhu XD Cancer Med; 2019 Nov; 8(15):6604-6613. PubMed ID: 31517443 [TBL] [Abstract][Full Text] [Related]
35. Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Minami S; Ihara S; Nishimatsu K; Komuta K World J Oncol; 2019 Dec; 10(6):187-198. PubMed ID: 31921375 [TBL] [Abstract][Full Text] [Related]
36. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy. Yılmaz U; Ozdemir O; Batum O; Ermin S Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894 [TBL] [Abstract][Full Text] [Related]
37. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080 [TBL] [Abstract][Full Text] [Related]
38. The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Sakin A; Sahin S; Atci MM; Sakin A; Yasar N; Geredeli C; Aksaray F; Cihan S Pulmonology; 2021; 27(1):26-34. PubMed ID: 31839507 [TBL] [Abstract][Full Text] [Related]
39. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation]. Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771 [No Abstract] [Full Text] [Related]
40. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR; J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]